United Therapeutics (UTHR) Cash from Financing Activities (2009 - 2026)

United Therapeutics has reported Cash from Financing Activities for 18 years, with the latest figure at -$1.5 billion in Q1 2026.

• Quarterly Cash from Financing Activities fell 1482.52% year-over-year to -$1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.5 billion (down 805.42% YoY) and the FY2025 annual result came in at -$1.2 billion, up 8.35% from the prior year.
• Cash from Financing Activities slipped to -$1.5 billion in Q1 2026 per UTHR's latest filing, from $98.4 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $98.4 million in Q4 2025 and troughed at -$1.5 billion in Q1 2026.
• A 5-year average of -$225.0 million and a median of -$48.0 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities surged 640.0% in 2022, then tumbled 2297.53% in 2024.
• Over 5 years, Cash from Financing Activities stood at $55.5 million in 2022, then sank by 267.21% to -$92.8 million in 2023, then gained by 19.5% to -$74.7 million in 2024, then surged by 231.73% to $98.4 million in 2025, then tumbled by 1608.54% to -$1.5 billion in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$1.5 billion, $98.4 million, and -$956.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.